CompletedPHASE1, PHASE2NCT00517517
Safety and Immunogenicity Study of Two Doses of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)
Studying Avian influenza
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alachua Government Services, Inc.
- Principal Investigator
- Baxter Bio Science InvestigatorBaxter Healthcare Corporation
- Intervention
- Whole virion, Vero cell-derived influenza vaccine containing either 3.75 µg or 7.5 µg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation(biological)
- Enrollment
- 110 enrolled
- Eligibility
- 21-45 years · All sexes
- Timeline
- 2007 – 2008
Study locations (4)
- University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
- Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong
- National University Hospital, Singapore, Singapore
- Changi General Hospital, Singapore, Singapore
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00517517 on ClinicalTrials.govOther trials for Avian influenza
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07496450A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy AdultsModernaTX, Inc.
- RECRUITINGPHASE3NCT07240558Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial)University Health Network, Toronto
- ACTIVE NOT RECRUITINGPHASE4NCT07275060Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks ApartCanadian Immunization Research Network
- RECRUITINGPHASE1, PHASE2NCT06842173Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older AdultsButantan Institute
- ACTIVE NOT RECRUITINGPHASE1NCT07019883A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy AdultsNational Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGNANCT06850298H5N1 Milk Detection StudyEmory University